Novel metal-based anticancer drugs: A new challenge in drug delivery

Current Opinion in Pharmacology

Volumn 12, Issue 4, 2012, Pages 420-426

  Lainé, Anne Laure ^a,b   Passirani, Catherine ^a,b  

^a LUNAM Univ Ingenierie de la Vectorisation Particulaire in Macro et Nanomedecines Biomimetiques   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AURANOFIN; CISPLATIN; DENDRIMER; FERROCIPHENOL; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; KP 1339; LIPOPLATIN; LIPOSOME; NAMI A; NANOCARRIER; NC 6004; PACLITAXEL; PRODRUG; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LUNG NON SMALL CELL CANCER; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; METALS; MOLECULAR STRUCTURE; NEOPLASMS;

EID: 84865029276     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.04.006     Document Type: Review

References (48)

1. B. Rosenberg, L. VanCamp, J.E. Trosko, and V.H. Mansour Platinum compounds: a new class of potent antitumour agents Nature 222 1969 385 386
2. M. Galanski, M.A. Jakupec, and B.K. Keppler Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches Curr Med Chem 12 2005 2075 2094
3. A. Sandler, C. Graham, M. Baggstrom, R. Herbst, C. Zergebel, K. Saito, and D. Jones An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer J Thorac Oncol 6 2011 1400 1406
4. Y. Jung, and S.J. Lippard Direct cellular responses to platinum-induced DNA damage Chem Rev 107 2007 1387 1407
5. N. Pabla, and Z. Dong Cisplatin nephrotoxicity: mechanisms and renoprotective strategies Kidney Int 73 2008 994 1007
6. W. Dempke, W. Voigt, A. Grothey, B.T. Hill, and H.J. Schmoll Cisplatin resistance and oncogenes - a review Anticancer Drugs 11 2000 225 236
7. C.G. Hartinger, M.A. Jakupec, S. Zorbas-Seifried, M. Groessl, A. Egger, W. Berger, H. Zorbas, P.J. Dyson, and B.K. Keppler KP1019, a new redox-active anticancer agent - preclinical development and results of a clinical phase I study in tumor patients Chem Biodivers 5 2008 2140 2155
8. I. Kostova Ruthenium complexes as anticancer agents Curr Med Chem 13 2006 1085 1107
9. R. Rubbiani, I. Kitanovic, H. Alborzinia, S. Can, A. Kitanovic, L.A. Onambele, M. Stefanopoulou, Y. Geldmacher, W.S. Sheldrick, and G. Wolber Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties J Med Chem 53 2010 8608 8618
10. E. Hillard, A. Vessières, L. Thouin, G. Jaouen, and C. Amatore Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates Angew Chem Int Ed Engl 45 2005 285 290
11. J. Claffey, H. Müller-Bunz, and M. Tacke Benzyl-substituted titanocene dichloride anticancer drugs: from lead to hit J Organomet Chem 695 2010 2105 2117
12. Z. Liu, A. Habtemariam, A.M. Pizarro, S.A. Fletcher, A. Kisova, O. Vrana, L. Salassa, P.C.A. Bruijnincx, G.J. Clarkson, and V. Brabec Organometallic half-sandwich iridium anticancer complexes J Med Chem 54 2011 3011 3026
13. S.H. van Rijt, and P.J. Sadler Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs Drug Discov Today 14 2009 1089 1097
14. S.J. Tan, Y.K. Yan, P.P.F. Lee, and K.H. Lim Copper, gold and silver compounds as potential new anti-tumor metallodrugs Future Med Chem 2 2010 1591 1608
15. G. Gasser, I. Ott, and N. Metzler-Nolte Organometallic anticancer compounds J Med Chem 54 2011 3 25
16. C. Ríos-Luci, L.G. León, A. Mena-Cruz, E. Pérez-Roth, P. Lorenzo-Luis, A. Romerosa, and J.M. Padrón Antiproliferative activity of dmoPTA-Ru(II) complexes against human solid tumor cells Bioorg Med Chem Lett 21 2011 4568 4571
17. C.G. Hartinger, S. Zorbas-Seifried, M.A. Jakupec, B. Kynast, H. Zorbas, and B.K. Keppler From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H- indazole)ruthenate(III)] (KP1019 or FFC14A) J Inorg Biochem 100 2006 891 904
18. M.B. Calvo, A. Figueroa, E.G. Pulido, R.G. Campelo, and L.A. Aparicio Potential role of sugar transporters in cancer and their relationship with anticancer therapy Int J Endocrinol 2010 2010 1 14
19. G. Russell-Jones, K. McTavish, and J. McEwan Preliminary studies on the selective accumulation of vitamin-targeted polymers within tumors J Drug Target 19 2011 133 139
20. 12 as a carrier for targeted platinum delivery: in vitro cytotoxicity and mechanistic studies J Biol Inorg Chem 16 2011 33 44
21. S.H. van Rijt, H. Kostrhunova, V. Brabec, and P.J. Sadler Functionalization of osmium arene anticancer complexes with (poly)arginine: effect on cellular uptake, internalization, and cytotoxicity Bioconjug Chem 22 2011 218 226
22. A.F.A. Peacock, S. Parsons, and P.J. Sadler Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity J Am Chem Soc 129 2007 3348 3357
23. L. Cubo, A.M. Pizarro, A.G. Quiroga, L. Salassa, C. Navarro-Ranninger, and P.J. Sadler Photoactivation of trans diamine platinum complexes in aqueous solution and effect on reactivity towards nucleotides J Inorg Biochem 104 2010 909 918
24. S. Dhar, N. Kolishetti, S.J. Lippard, and O.C. Farokhzad Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo Proc Natl Acad Sci U S A 108 2011 1850 1855
25. Y. Shi, S.-A. Liu, D.J. Kerwood, J. Goodisman, and J.C. Dabrowiak Pt(IV) complexes as prodrugs for cisplatin J Inorg Biochem 107 2012 6 14
26. H. Xiao, R. Qi, S. Liu, X. Hu, T. Duan, Y. Zheng, Y. Huang, and X. Jing Biodegradable polymer-cisplatin(IV) conjugate as a pro-drug of cisplatin(II) Biomaterials 32 2011 7732 7739
27. B.W. Harper, A.M. Krause-Heuer, M.P. Grant, M. Manohar, K.B. Garbutcheon-Singh, and J.R. Aldrich-Wright Advances in platinum chemotherapeutics Chemistry 16 2010 7064 7077
28. R. Misra, S. Acharya, and S.K. Sahoo Cancer nanotechnology: application of nanotechnology in cancer therapy Drug Discov Today 15 2010 842 850
29. S. Kunjachan, A. Błauż, D. Möckel, B. Theek, F. Kiessling, T. Etrych, K. Ulbrich, L. van Bloois, G. Storm, G. Bartosz, B. Rychlik, and T. Lammers Overcoming cellular multidrug resistance using classical nanomedicine formulations Eur J Pharm Sci 45 2012 421 428
30. B. Mirtsching, T. Cosgriff, G. Harker, M. Keaton, T. Chidiac, and M. Min A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer Clin Breast Cancer 11 2011 121 128
31. V. López-Dávila, A.M. Seifalian, and M. Loizidou Organic nanocarriers for cancer drug delivery Curr Opin Pharmacol 12 2012 414 419
32. M. Baba, Y. Matsumoto, A. Kashio, H. Cabral, N. Nishiyama, K. Kataoka, and T. Yamasoba Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs J Control Rel 157 2012 112 117
33. U. Kedar, P. Phutane, S. Shidhaye, and V. Kadam Advances in polymeric micelles for drug delivery and tumor targeting Nanomed: Nanotechnol Biol Med 6 2010 714 729
34. G.P. Stathopoulos, and T. Boulikas Lipoplatin formulation review article J Drug Deliv 2012 2012 581363
35. T. Boulikas Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts Oncol Rep 12 2004 3 12
36. P. Devarajan, R. Tarabishi, J. Mishra, Q. Ma, A. Kourvetaris, M. Vougiouka, and T. Boulikas Low renal toxicity of Lipoplatin compared to cisplatin in animals Anticancer Res 24 2004 2193 2200
37. G.P. Stathopoulos, D. Antoniou, J. Dimitroulis, J. Stathopoulos, K. Marosis, and P. Michalopoulou Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer Cancer Chemother Pharmacol 68 2011 945 950
38. L. Cheng, C. Jin, W. Lv, Q. Ding, and X. Han Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer PLoS One 6 2011 e25433
39. G.J. Kirkpatrick, J.A. Plumb, O.B. Sutcliffe, D.J. Flint, and N.J. Wheate Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin J Inorg Biochem 105 2011 1115 1122
40. A. Vessières, S. Top, P. Pigeon, E. Hillard, L. Boubeker, D. Spera, and G. Jaouen Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro J Med Chem 48 2005 3937 3940
41. E. Allard, N.T. Huynh, A. Vessières, P. Pigeon, G. Jaouen, J.-P. Benoit, and C. Passirani Dose effect activity of ferrocifen-loaded lipid nanocapsules on a 9L-glioma model Int J Pharm 379 2009 317 323
42. N.T. Huynh, C. Passirani, P. Saulnier, and J.P. Benoit Lipid nanocapsules: a new platform for nanomedicine Int J Pharm 379 2009 201 209
43. N.T. Huynh, C. Passirani, E. Allard-Vannier, L. Lemaire, J. Roux, E. Garcion, A. Vessieres, and J.-P. Benoit Administration-dependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma Int J Pharm 423 2012 55 62
44. N.T. Huynh, M. Morille, J. Bejaud, P. Legras, A. Vessieres, G. Jaouen, J.-P. Benoit, and C. Passirani Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect Pharm Res 28 2011 3189 3198
45. V.K. Yellepeddi, A. Kumar, D.M. Maher, S.C. Chauhan, K.K. Vangara, and S. Palakurthi Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT Anticancer Res 31 2011 897 906
46. N.T. Huynh, E. Roger, N. Lautram, J.-P. Benoît, and C. Passirani The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting Nanomedicine (Lond) 5 2010 1415 1433
47. B. Mishra, B.B. Patel, and S. Tiwari Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery Nanomed: Nanotechnol Biol Med 6 2010 9 24
48. A.-L. Laine, N.T. Huynh, A. Clavreul, J. Balzeau, J. Béjaud, A. Vessieres, J.-P. Benoit, J. Eyer, and C. Passirani Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules Eur J Pharm Biopharm 81 2012 690 693